Soad Haj Yahia, Diti Machnes-Maayan, Shirly Frizinsky, Ramit Maoz-Segal, Irena Offenganden, Ron S Kenett, Nancy Agmon-Levin, Ran Hovav, Mona I Kidon
BACKGROUND: Between 25%-30% of peanut allergic (PA) children, have a relatively high threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates. OBJECTIVE: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol, in a group of children with HTPA. METHODS: PA children with an SMTD higher than 100mg, were placed on a 40 week OIT protocol of either 300 mg/day of PP or 100 mg/day for 20 weeks followed by 300 mg/day for 20 weeks...
May 9, 2022: Annals of Allergy, Asthma & Immunology